Weight Loss Injections & Mental Health

How does Wegovy affect mental health?

The link between weight and mental health is far from straightforward. Weight struggles can worsen existing mental health issues and sometimes even contribute to new ones. One study found that about 2 in 5 people with overweight or obesity also have a psychiatric disorder, like anxiety or depression.

So weight loss injections (WLIs) may help some people feel better emotionally by addressing one of the main sources of distress: the extra weight.

Medically reviewed by

Craig Marsh, Independent Prescriber

Improved self-image

Many people prefer their appearance after losing weight, which often improves body satisfaction, mood, and overall quality of life.

Interestingly, these psychosocial gains don’t always correlate with the amount of weight loss, which could suggest—purely speculatively—that even the process of trying to lose weight may offer meaningful mental health benefits.

Reduced food noise

People with obesity often experience what’s been called “food noise”, which basically refers to constant thoughts about what, when, or how much to eat, often accompanied by guilt.

Recent research suggests that GLP‑1 receptor agonists (the drugs used in WLIs) can reduce this mental clutter by lowering appetite signals, cravings, and preoccupation with food.

Anecdotally, users report that fewer intrusive food thoughts can free cognitive and emotional bandwidth for work, relationships, hobbies, or other areas that were previously overshadowed by constant food-related worry.

But more research is needed to fully measure this “freeing up” effect.

Less alcohol and substance use

Still-ongoing research suggests that WLIs can help with other addictive behaviours and substance misuse, including alcohol and smoking.

A recent randomised clinical trial found that once-weekly semaglutide (the active drug in Ozempic and Wegovy) reduced both craving for and consumption of alcohol over nine weeks of treatment. The same study also linked semaglutide to a reduction in smoking.

If WLIs decrease substance use (like alcohol and smoking), this could in turn reduce mood disorders, anxiety, and the social or work-related harms often associated with addiction — another way in which these medications can support mental health.

An ongoing trial is currently investigating semaglutide’s potential to reduce alcohol consumption.

Healthier eating patterns

GLP-1s have reduced binge eating and emotional eating behaviours in several clinical and observational studies. Participants in these studies often report:

more regular meals,
smaller portion sizes,
and less impulsive snacking.

These behavioural shifts are partly due to appetite suppression and changes in the brain’s reward system.

Being more intentional with eating might have a knock-on effect on your overall health, including mental health. Improved eating habits support better nutrient intake, stronger satiety signals, and more balanced blood sugar levels, which are all linked to better mood and energy.

There’s also growing interest in GLP-1’s effects on the gut-brain axis. Though more research is needed, GLP-1s might help regulate mood by promoting the growth of “good” gut bacteria, improving gut health, and correcting nutrient deficiencies.

Reduced inflammation

When neuroinflammation (inflammation in the brain) affects your brain, it can disrupt levels of important brain chemicals like noradrenaline, serotonin, and dopamine, which can trigger anxiety and depression.

Studies in animals show that GLP-1s can help tone down neuroinflammation, which means they could have protective effects on thinking and mood.

But human data linking reduced neuroinflammation to improved mood are still sparse, so more research is needed before we can pin this down as a clear route to better mental health.

Exercise is more enjoyable (and more frequent)

Being overweight can make movement uncomfortable and leave some people feeling self-conscious, especially in the gym or group classes.

But losing weight can:

take the pressure off your joints,
reduce exertion,
and improve confidence.

Plus, exercise releases endorphins that reduce stress and can help lift your mood.

Category	Findings
Gender	Women are at higher risk than men: about twice as likely for anxiety and 2.5 times as likely for suicidal thoughts.
Age	Younger adults (18–49) were about three times more likely than the reference group to experience suicidal thoughts or attempts.
Race	Patients of Black African origin have a higher risk of suicidal thoughts or attempts compared to White and Asian patients.
Dose effects	Higher doses of liraglutide (2.4–3.0 mg) are linked to slightly more psychiatric events, especially insomnia, low mood, and nervousness.
STEP clinical studies	Incidence of psychiatric events were generally uncommon, though rates varied between drugs and doses: Liraglutide 3 mg: 15%; Semaglutide 2.4 mg: 3%-6%; Placebo: 1%-10.6%.
Case reports	Two people developed depression shortly after starting semaglutide, but improved quickly after stopping.
Real-world studies	FDA data at first flagged reports of depression and suicidal thoughts, but once other factors were taken into account, no direct link was found. Real-world studies suggest that semaglutide doesn’t raise suicidal thoughts and might even help ease anxiety in people with diabetes.

Struggling with side effects

Early side effects like nausea, vomiting, dizziness, and fatigue are common when starting GLP-1s, especially while titrating the dose. These can knock your mood and make day-to-day life more difficult, especially if they’re persistent or severe.

There have also been reports of mood changes, depression, and suicidal thoughts, which is why regulators like the FDA, EMA, and MHRA keep a close eye on WLIs.

One study found that GLP-1 treatment was associated with a higher risk for psychiatric disorders:

195% for major depression,
108% for anxiety,
and 106% for suicidal behaviour.

That said, large trials tell a much more reassuring story. Pooled data from over 3,000 people using semaglutide found no clear increase in depression or suicidal behaviour in those without major mental health conditions. In fact, semaglutide was linked to a small drop in depressive symptoms (though not considered clinically meaningful).

However, your risk of experiencing psychiatric side effects might be increased by factors like:

pre-existing mental health conditions,
family history of mental health conditions,
recent stress,
and using other medications at the same time.

Long story short: Evidence is mixed. Most large studies don’t show a direct link between GLP-1s and serious psychiatric events, but some case reports suggest caution, especially if you already have risk factors like a family history or existing mental health issues.

Body dysmorphia

Whether influenced by social media, external pressure, or personal beliefs, it’s sometimes easy for some people to tie their self-worth to their appearance.

Rapid weight changes can stir up or worsen body-image worries, leading some to obsess over how they look, chase further changes, or feel constant pressure to keep the weight off, which can fuel anxiety, unhealthy habits, and self-criticism.

While this is most common after major weight loss like bariatric surgery, it’s possible that pharmacological weight loss could set off similar concerns. This is why screening for body-image issues before starting treatment can help clinicians identify who might benefit from psychological support along the way.

Less enjoyment from food and other activities

Some people on WLIs notice a dulling of pleasure from food and, occasionally, other activities (a disorder called anhedonia). This happens because GLP-1s tinker with the brain’s dopamine “reward” system: they can rev up dopamine in some areas while dialing it down in others, which can reduce the “feel-good” signals from things that used to be pleasurable.

While changes in appetite and food reward are a welcome side effect for most people, for a minority, this can spill over into other aspects of life, leaving them feeling flat or less motivated.

However, evidence is mostly anecdotal or from small studies, so it’s something to be aware of, not a guaranteed effect.

Relationship problems

Some people on GLP-1s have reported sexual side effects like lower libido, difficulties reaching orgasm, or erectile dysfunction. Controlled trials, however, haven’t flagged major sexual problems, so the evidence is mixed and still evolving.

Weight loss has also been linked to relationship problems. One study suggest that adults who underwent bariatric surgery were more than twice as likely to get divorced within five years compared to the general U.S. population.

For GLP-1 users, large studies are lacking, but clinical experience and media stories suggest relationship changes can happen and should be talked through during counselling.

Unmet expectations

It’s common to expect that losing weight will “fix” some if not all emotional problems. And for many people, it does improve self-esteem and mood. But for others, it can expose deeper issues, like chronic depression, past trauma, or relationship problems, that go beyond what weight loss alone can fix.

Also, sometimes GLP-1 medication just doesn’t work as well as you’d hoped, or even when the treatment is successful, the emotional payoff doesn’t quite live up to your expectations. And when this happens, it can affect your mood or leave you feeling disappointed.

That’s why it can help to set realistic goals before starting treatment, recognise that weight loss isn’t a cure-all, and be open to psychological support as part of your treatment when needed.